Celltrion posts Q2 operating profit of 451.8 billion won, up 86.3% on biosimilar sales and wider margins
AI Market Summary
Celltrion reported record Q2 results with revenue up 45% y/y and operating profit up 86.3%, as new biosimilar launches lifted mix and manufacturing efficiency improved, pushing operating margin to 32.4%. Management raised full-year guidance above prior targets, reinforcing confidence in sustained operating leverage and pipeline reinvestment capacity. While impactful for Korean biotech equities, the news has limited immediate read-through to broad global macro markets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.96%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
South Korea’s biopharmaceutical company Celltrion reported 2024 second-quarter revenue of 1.39 trillion won and operating profit of 451.8 billion won, up 45% and 86.3% year over year. Its operating margin rose to 32.4% as the sales mix shifted toward newly launched biosimilars and costs improved. New products accounted for 65% of biosimilar sales, supported by continued optimization of the cost structure. The company raised its full-year outlook, saying revenue and operating profit are expected to exceed its previously announced targets of 5.3 trillion won and 1.8 trillion won.
